Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations? Results from a Large Cohort of Patients with Severe Uncontrolled Asthma

Chest

Volumn 143, Issue 2, 2013, Pages 398-405

  Grimaldi Bensouda, Lamiae ^a,b   Zureik, Mahmoud ^c   Aubier, Michel ^d   Humbert, Marc ^e,f,g   Levy, Jean ^h   Benichou, Jacques ^i,j   Molimard, Mathieu ^j,k,l   Abenhaim, Lucien ^m,n  

^a LA SER   (France)

^b INSTITUT PASTEUR   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f BICÊTRE HOSPITAL   (France)

^g CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^h Clinique de Pneumologie   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j INSERM U657   (France)

^k UNIVERSITÉ DE BORDEAUX   (France)

^l BORDEAUX UNIVERSITY HOSPITAL   (France)

^m LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁿ London School of Hygiene Tropical Medicine   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; OMALIZUMAB; PREDNISONE;

ADD ON THERAPY; ADULT; AGE; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ARTICLE; BODY MASS; COHORT ANALYSIS; COMORBIDITY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; GASTROESOPHAGEAL REFLUX; GENDER; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING;

EID: 84874079268     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1372     Document Type: Article

References (17)

1. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004; 59 (5): 469-478.
2. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life Geneva, Switzerland: World Health Organization; 2002.
3. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med. 2000; 162 (6): 2341-2351.
4. GINA report: global strategy for asthma management and prevention. Global Initiative for Asthma website. http://www.ginasthma.org. Accessed June 20, 2011.
5. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31 (1): 143-178.
6. Price D. The use of omalizumab in asthma. Prim Care Respir J. 2008; 17 (2): 62-72.
7. Murphy P, Hillman T, Rajakulasingam K. Therapeutic targets for persistent airway infl ammation in refractory asthma. Biomed Pharmacother. 2010; 64 (2): 140-145.
8. European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J. 2003; 22 (3): 470-477.
9. Dolan CM, Fraher KE, Bleecker ER, et al; TENOR Study Group. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004; 92 (1): 32-39.
10. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60 (3): 309-316.
11. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000; 356(9237): 1255-1259.
12. Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003; 19 (6): 491-498.
13. Andersen PK, Gill RD. Cox's regression model for counting process: a large sample study. Ann Stat. 1982; 10(4): 1100-1120.
14. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001; 18 (2): 254-261.
15. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti- IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108 (2): 184-190.
16. Holgate ST, Chuchalin AG, Hébert J, et al; Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004; 34 (4): 632-638.
17. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011; 139 (1): 28-35.